Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06127966 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Relationship Between NLR and PONV and ESPB

StatusNot Yet Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 29, 2025 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jun 2025 to Aug 1, 2026
    • Start date: Nov 2024 to Aug 1, 2025
    • Study completion date: Sep 2025 to Sep 1, 2026
    • Eligibility criteria expanded, about 36 words
    v3
  2. Start date: Nov 2023 to Nov 2024v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to investigate whether preoperative NLR (Neutrophil-to-Lymphocyte Ratio) serves as a biomarker for PONV (Postoperative Nausea and Vomiting). It also examines the impact of erector spinae plane block on NLR and PONV. Furthermore, the research explores the effect of erector spinae plane block on postoperative pain relief in spinal surgery and its influence on the usage of opioid medications.
Trial Details
NCT Number NCT06127966
Lead Sponsor Qianfoshan Hospital
Conditions
(from sponsor)		 Erector Spinae Plane Block, Neutrophil to Lymphocyte Ratio
Related terms Postoperative Nausea and Vomiting
Enrollment 220 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov